Figure 2. Antiviral efficacies of entecavir (ETV) treatment according to prior lamivudine use in the two study groups. (A) Kaplan-Meier curve for the cumulative probabilities of achieving virologic response. (B) Comparison of the hepatitis B e antigen (HBeAg) loss probabilities during ETV therapy. (C) Comparison of the HBeAg seroconversion probabilities during ETV therapy. (D) Comparison of the ALT normalization probabilities during ETV therapy. LAM, lamivudine; NA, nucleos(t)ide analogue; ALT, alanine aminotransferase.